RNAC – cartesian therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at BTIG Research. They set a "buy" rating and a $42.00 price target on the stock.
Cartesian Therapeutics Announces New Employment Inducement Grants
Arthrosi Appoints John Leaman, M.D., to Its Board of Directors [Yahoo! Finance]
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock, up previously from $41.00.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
Form S-3 Cartesian Therapeutics,
Form S-3 Cartesian Therapeutics,
Form S-3 Cartesian Therapeutics,
Form 4 Cartesian Therapeutics, For: Dec 09 Filed by: Kurtoglu Metin
Form 144 Cartesian Therapeutics, Filed by: Kurtoglu Metin
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.